Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutent in Advanced Hepatocellular Carcinoma
NCT00495625Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2006
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in hepatocellular carcinoma (HCC), sponsored by Moffitt Cancer Center. Primary endpoints: Partial Response at 7 months, Stable Disease at 7 months and 1 more. Started Oct 2006; status: terminated.
02
Drugs
sunitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00495625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00495625.